Journal article
IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas
SV Liubinas, GM D'Abaco, BM Moffat, M Gonzales, F Feleppa, CJ Nowell, A Gorelik, KJ Drummond, TJ O'Brien, AH Kaye, AP Morokoff
Epilepsia | WILEY | Published : 2014
DOI: 10.1111/epi.12662
Abstract
Objective: The isocitrate dehydrogenase 1 (IDH1) R132H mutation is the most common mutation in World Health Organization (WHO) grade II gliomas, reported to be expressed in 70-80%, but only 5-10% of high grade gliomas. Low grade tumors, especially the protoplasmic subtype, have the highest incidence of tumor associated epilepsy (TAE). The IDH1 mutation leads to the accumulation of 2-hydroxyglutarate (2HG), a metabolite that bears a close structural similarity to glutamate, an excitatory neurotransmitter that has been implicated in the pathogenesis of TAE. We hypothesized that expression of mutated IDH1 may play a role in the pathogenesis of TAE in low grade gliomas.Methods: Thirty consecutiv..
View full abstractRelated Projects (2)
Grants
Funding Acknowledgements
National Health and Medical Research Council (Australia) grant number 628301. National Health and Medical Research Council (Australia) postgraduate research scholarship 2012. Royal Australasian College of Surgeons Foundation for Surgical Research Scholarship, 2011 and 2012. Melville Hughes Scholarship, The University of Melbourne, 2010.